Ventilator-Associated Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Vietnam: Antibiotic Resistance, Treatment Outcomes, and Colistin-Associated Adverse Effects

Vo, Thu Pham Minh; Dinh, Thien Chi; Phan, Hung Viet; Cao, Thuy Thi My; Duong, Phuoc Thien; Nguyễn, Thắng

doi:10.3390/healthcare10091765

Cited by 6 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Severe infectious diseases caused by MDR GNB, especially COL-R GNB, include nosocomial pneumonia (ventilator-associated pneumonia), urinary tract infection, and infectious diseases of other sites. These are among the most serious complications that occur in the clinical treatment setting. − Mortality, morbidity, and healthcare costs are substantially increasing each year.…”

Section: Discussionmentioning

confidence: 99%

“…Considered among the few last-resort antibiotics, COL is applied to treat infectious diseases caused by MDR and carbapenem-resistant GNB. Unfortunately, the emergence of colistin-resistant (COL-R) GNB has already been reported, − which means choosing appropriate antibiotics for the clinical treatment of infectious diseases caused by these pathogens is more difficult. , This also indicates that AMR prevention and exploration of novel antimicrobial therapy, as well as medicine control, are crucial for optimizing patient health management and outcomes. , …”

Section: Discussionmentioning

confidence: 99%

“…After the cell suspension was incubated for the whole day, 10 μL of serial concentrations of BT (4,8,16,32, and 64 μg/mL) was added to the medium, and culturing was continued for 24 and 72 h, respectively. The wells containing saline and the solvent (DMSO) were used as control groups.…”

Section: ■ Materials and Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Bithionol Restores Sensitivity of Multidrug-Resistant Gram-Negative Bacteria to Colistin with Antimicrobial and Anti-biofilm Effects

et al. 2023

View full text Add to dashboard Cite

Being among the few last-resort antibiotics, colistin (COL) has been used to treat severe infectious diseases, such as those caused by multidrugresistant Gram-negative bacteria (MDR GNB). However, the appearance of colistin-resistant (COL-R) GNB has been frequently reported. Therefore, novel antimicrobial strategies need to be urgently sought to address this resistance challenge. In the present study, antimicrobial drug screening conducted revealed that bithionol (BT), approved by the Food and Drug Administration and used as an anthelminthic drug for paragonimiasis, exhibited a synergistic antibacterial effect with COL. Clinically isolated COL-R GNB were used as candidates to evaluate the synergistic antibacterial activity. The results revealed that BT could significantly reverse the sensitivity of COL-R GNB to COL. Furthermore, the combined application of BT and COL can reduce bacterial biofilm formation and have a scavenging effect on the mature biofilm in vitro. The damage caused to the bacterial cell membrane integrity by the BT/COL combination was observed under a fluorescence microscope. The fluorescence intensity of reactive oxygen species also increased in the experimental group. The BT/COL combination also exhibited a synergistic antibacterial effect in vivo. Importantly, BT was confirmed to be safe at the highest concentrations that exerted synergistic effects on all tested strains. In conclusion, our findings demonstrated that BT exerted synergistic antimicrobial and anti-biofilm effects when combined with COL against MDR organisms, especially COL-R GNB, in vitro and in vivo. The findings thus provide a reference for the clinical response to the serious challenge of MDR GNB and the exploitation of the potential antibacterial activities of existing clinical non-antibacterial drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bithionol Restores Sensitivity of Multidrug-Resistant Gram-Negative Bacteria to Colistin with Antimicrobial and Anti-biofilm Effects

et al. 2023

View full text Add to dashboard Cite

show abstract

“…96 A prospective cohort research done in 2022 on MDR Gram-negative pathogens recovered from intubated patients with VAP showed colistin resistance rates of 3-20% among MDR A. baumannii, K. pneumoniae, as well as P. aeruginosa. 97 Also, in a 5-year retrospective study following over 5,500 patients in four general ICUs in Barcelona, Spain, the rate of colistin resistance among P. aeruginosa isolated from HAP or VAP specimens was 15%. 98 These numbers warrant careful attention to colistin use, and thorough re-evaluation of its introduction to antimicrobial therapy.…”

Section: Carbapenem-resistant Enterobacterales (Cre)mentioning

confidence: 99%

Bacterial pneumonia associated with multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19

Halat

Moubareck

2023

F1000Res

View full text Add to dashboard Cite

The ongoing spread of antimicrobial resistance has complicated the treatment of bacterial hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Gram-negative pathogens, especially those with multidrug-resistant profiles, including Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Pseudomonas aeruginosa, and Acinetobacter spp., are an important culprit in this type of infections. Understanding the determinants of resistance in pathogens causing pneumonia is ultimately stressing, especially in the shadows of the COVID-19 pandemic, when bacterial lung infections are considered a top priority that has become urgent to revise. Globally, the increasing prevalence of these pathogens in respiratory samples represents a significant infection challenge, with major limitations of treatment options and poor clinical outcomes. This review will focus on the epidemiology of HAP and VAP and will present the roles and the antimicrobial resistance patterns of implicated multidrug-resistant (MDR) Gram-negative pathogens like carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Enterobacterales (CRE), as well as colistin-resistant Gram-negative pathogens and extended-spectrum β-lactamase (ESBL)-producing Enterobacterales. While emerging from the COVID-19 pandemic, perspectives and conclusions are drawn from findings of HAP and VAP caused by MDR Gram-negative bacteria in patients with COVID-19.

show abstract

“…This was associated with more capillary lung lesions and bilateral disease, which required more prolonged treatment [125]. Also, more than half of S. aureus strains tested were MDR, showing resistance to fluoroquinolones [126][127][128]. Efforts have been made to improve the fluoroquinolones' potency, for example, by conjugate biofilm formation, a major virulence factor of Pseudomonas auroginosa that causes antibiotic resistance [129].…”

Section: Toxicity Study Of Nsaids and Fluoroquinolones Multi-componen...mentioning

confidence: 99%

The Benefits and Challenges of Antibiotics–Non-Steroidal Anti-Inflammatory Drugs Non-Covalent Reaction

2023

View full text Add to dashboard Cite

Recently, non-covalent reactions have emerged as approaches to improve the physicochemical properties of active pharmaceutical ingredients (API), including antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). This review aimed to present and discuss the non-covalent reaction products of antibiotics, including salt and neutral multi-component solid forms, by framing their substituents and molar ratios, manufacturing techniques, characterization methods, benefits, potency changes, and toxicity, and is completed with an analysis of the development of computational models used in this field. Based on the data, NSAIDs are the most-developed drugs in multi-component system preparations, followed by antibiotics, i.e., antituberculosis and fluoroquinolones. They have reacted with inorganic elements, excipients, nutraceuticals, natural products, and other drugs. However, in terms of treatments for common infections, fluoroquinolones are more frequently used. Generally, NSAIDs are acquired on an over-the-counter basis, causing inappropriate medication. In addition, the pKa differences between the two groups of medicine offer the potential for them to react non-covalently. Hence, this review highlights fluoroquinolone–NSAID multi-component solid systems, which offer some benefits. These systems can increase patient compliance and promote the appropriate monitoring of drug usage; the dual drug multi-component solids have been proven to improve the physicochemical properties of one or both components, especially in terms of solubility and stability. In addition, some reports show an enhancement of the antibiotic activity of the products. However, it is important to consider the possibility of activity changes, interaction, and toxicity when using drug combinations. Hence, these aspects also are discussed in this review. Finally, we present computational modeling, which has been utilized broadly to support multi-component system designs, including coformer screening, preparation methods, and structural modeling, as well as to predict physicochemical properties, potency, and toxicity. This integrated review is expected to be useful for further antibiotic–NSAID multi-component system development.

show abstract

Ventilator-Associated Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Vietnam: Antibiotic Resistance, Treatment Outcomes, and Colistin-Associated Adverse Effects

Cited by 6 publications

References 19 publications

Bithionol Restores Sensitivity of Multidrug-Resistant Gram-Negative Bacteria to Colistin with Antimicrobial and Anti-biofilm Effects

Bithionol Restores Sensitivity of Multidrug-Resistant Gram-Negative Bacteria to Colistin with Antimicrobial and Anti-biofilm Effects

Bacterial pneumonia associated with multidrug-resistant Gram-negative pathogens: Understanding epidemiology, resistance patterns, and implications with COVID-19

The Benefits and Challenges of Antibiotics–Non-Steroidal Anti-Inflammatory Drugs Non-Covalent Reaction

Contact Info

Product

Resources

About